JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response.,Clinical Immunology

当前位置： X-MOL 学术 › Clin. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response.
Clinical Immunology ( IF 4.5 ) Pub Date : 2019-11-05 , DOI: 10.1016/j.clim.2019.108297
Freidrich Anselmo ₁ , Alexandru Tatomir ₂ , Dallas Boodhoo ₁ , Armugam P Mekala ₁ , Vinh Nguyen ₃ , Violeta Rus ₃ , Horea Rus ₄

Affiliation

In this study, we investigated the role of JNK and phospho-Bcl-2 as possible biomarkers of multiple sclerosis (MS) relapse and of glatiramer acetate (GA) therapeutic response in relapsing-remitting MS patients. We enrolled a cohort of 15 GA-treated patients and measured the expression of JNK1, JNK2, phospho-JNK and phospho-Bcl-2 through Western blotting of lysates from peripheral blood mononuclear cells collected at 0, 3, 6, and 12 months after initiating GA therapy. We found significantly higher levels of JNK1 p54 and JNK2 p54 and significantly lower levels of p-Bcl-2 in relapse patients and in GA non-responders. By using receiver operating characteristic analysis, we found that the probability of accurately detecting relapse and response to GA was: 92% and 75.5%, respectively, for JNK1 p54 and 86% and 94.6%, respectively, for p-Bcl-2. Our data suggest that JNK1 and p-Bcl-2 could serve as potential biomarkers for MS relapse and the therapeutic response to GA.

中文翻译：

JNK和磷酸化的Bcl-2预测多发性硬化症的临床活动和醋酸格拉替雷的治疗反应。

在这项研究中，我们调查了JNK和磷酸化Bcl-2在复发缓解型MS患者中作为多发性硬化（MS）复发和醋酸格拉替雷（GA）治疗反应的可能生物标志物的作用。我们招募了15名接受GA治疗的患者，并通过Western印迹分别从分别在0、3、6和12个月后收集的外周血单核细胞的裂解物进行了JNK1，JNK2，磷酸化JNK和磷酸化Bcl-2的表达开始GA治疗。我们发现复发患者和GA无反应者中JNK1 p54和JNK2 p54的水平显着较高，而p-Bcl-2的水平显着较低。通过使用接收器工作特性分析，我们发现准确检测复发和对GA的反应的概率分别为：对于JNK1 p54，分别为92％和75.5％，对于p-Bcl-2，分别为86％和94.6％。

更新日期：2019-11-05

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11